Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of treating psoriasis using anti-gamma interferon antibody

a technology of gamma interferon and anti-psoriasis, which is applied in the field of treating psoriasis using gamma interferon antibody, can solve the problems that the model lacks certain histological hallmarks of the human body, and achieves the effect of improving the histological quality of the human body

Inactive Publication Date: 2003-03-20
FACET BIOTECH CORP
View PDF19 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This model, however, lacked certain distinctive histological hallmarks of the human disease and included some characteristics that are absent from human patients with psoriasis, Nickoloff et al.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating psoriasis using anti-gamma interferon antibody
  • Method of treating psoriasis using anti-gamma interferon antibody

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0067] Materials and Methods

[0068] Mice. Female BALB / cj mice and BALB / cj-IFN.gamma..sup.-1- mice (donor mice) were purchased from Jackson Labs (Bar Harbor, Me.). C.B-17 / 1cr scid / scid mice and C.B-17 scid-beige double mutant mice (recipient mice) were purchased from Taconic (Germantown, N.Y.). All mice were housed in a specific pathogen free environment at the Protein Design Labs animal facility and were used between 4-12 weeks of age. Sentinel mice were used to screen for the following pathogens: MHV, sendai, PVM, REO3, TMEV GDVIII, M. pulmonis and parvovirus. Random screens of mice for pinworms were also conducted. None of the pathogens listed above were detected at anytime. Mice were housed 2-5 per microsisolator. All scid / scid or scid / beige mice were handled with gloves under a class II hood, fed sterile food and water ad libitum, and maintained inside a laminar flow tent (Bioclean Maywood, N.J.) in sterile microisolators that were changed weekly. Donor mice were housed in conven...

example 2

[0102] Animals were tested for the effect of treatment with antibodies to IL-12 on on going and late-stage psoriatic disease. The disease was induced by the methods described in Example 1, i.e., using 3.times.10.sup.5 CD4.sup.+CD45Rb.sup.hi cells transferred into scid / scid mice followed by injection of LPS and IL-12. Treatment with the anti-IL-12 antibody was always at 1 mg / mouse / dose. The results of four separate experiments are shown in FIG. 1. In the initial experiment, (n=5 untreated; n=2 treated), the mice received injections of anti-IL-12 at weeks 9 and 10 (i.e., about 5 weeks after the appearance of psoriatic symptoms) and were sacrificed for histology at week 14. Whereas the untreated mice had an average histology score of 2.5, indicating moderate to high symptoms, the treated mice had a histology score of only 0.25, indicating almost no symptoms. Hence, two injections of the anti-IL-12 antibody were highly effective in alleviating established symptoms of psoriasis.

[0103] In...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
body weightaaaaaaaaaa
Login to View More

Abstract

Methods and compositions are provided for the creation and screening of non-human animal models having many of the histologic characteristics of human psoriasis. Immunocompromised host animals are injected with a purified population of CD45Rb positive cells, which are tolerant of the host major histocompatibility antigens, but are mismatched at one or more minor antigens. The injected cells are stimulated with a pro-inflammatory cytokine, e.g. IL-12, and a polyclonal activating agent. The injected animals develop a chronic skin disorder that includes histological features observed in human psoriasis, e.g. rete pegs, severe acanthosis and infiltration of Th1 cells into the dermis.

Description

[0001] Psoriasis is a chronic skin disease, characterized by scaling and inflammation. Psoriasis affects 1.5 to 2 percent of the United States population, or almost 5 million people. It occurs in all age groups and about equally in men and women. People with psoriasis suffer discomfort, restricted motion of joints, and emotional distress. When psoriasis develops, patches of skin thicken, redden, and become covered with silvery scales, referred to as plaques. Psoriasis most often occurs on the elbows, knees, scalp, lower back, face, palms, and soles of the feet. The disease also may affect the fingernails, toenails, and the soft tissues inside the mouth and genitalia. About 10 percent of people with psoriasis have joint inflammation that produces symptoms of arthritis.[0002] When skin is wounded, a wound healing program is triggered, also known as regenerative maturation. Lesional psoriasis is characterized by cell growth in this alternate growth program. In many ways, psoriatic skin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A01K67/027A61K39/395A61K35/12A61K39/00A61K49/00A61P17/06C07K16/24G01N33/15G01N33/50G01N33/566
CPCA01K67/0271A61K35/12A61K39/3955C07K16/24C07K16/244A61K2039/505A61K38/208A61P17/06C07K14/5434A61K39/00C07K2317/76
Inventor EHRHARDT, ROLFHONG, KENNETH
Owner FACET BIOTECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com